Why Start Fondaparinux in ACS?
Fondaparinux should be initiated in ACS patients primarily to reduce major bleeding complications while maintaining equivalent efficacy in preventing ischemic events, particularly in those not undergoing primary PCI or receiving fibrinolytic therapy. 1, 2
Key Clinical Scenarios for Fondaparinux Use
NSTE-ACS Without Early Invasive Strategy
Fondaparinux is a Class 1, Level B-R recommended alternative to UFH when early invasive management is not anticipated. 1, 2 The OASIS-5 trial demonstrated that fondaparinux was noninferior to enoxaparin for ischemic events at 9 days but reduced major bleeding by 50% (2.2% vs 4.1%, p<0.001), translating to improved 30-day mortality (295 vs 352 deaths, p=0.02) 1, 3.
STEMI With Fibrinolytic Therapy
For STEMI patients receiving fibrinolytics who are not intended for invasive management, fondaparinux is a Class 1, Level B-R recommended alternative. 1, 2 In OASIS-6, fondaparinux reduced death or reinfarction at 30 days (9.7% vs 11.2%, HR 0.86, p=0.008) with particular benefit in those receiving thrombolytics (HR 0.79, p=0.003) and those not receiving any reperfusion (HR 0.80, p=0.03) 4.
Mechanism of Benefit
Fondaparinux is a synthetic pentasaccharide that selectively inhibits Factor Xa through antithrombin binding, providing:
- Predictable anticoagulation with once-daily subcutaneous dosing (2.5 mg)
- Reduced bleeding risk compared to enoxaparin and UFH
- No heparin-induced thrombocytopenia risk
- Mortality benefit through bleeding reduction 2, 3
Critical Contraindication: PCI Support
Fondaparinux carries a Class 3: Harm, Level B-R recommendation for supporting PCI due to catheter thrombosis risk (0.9% vs 0.3% with enoxaparin). 1 If PCI becomes necessary in a patient on fondaparinux, add standard-dose UFH at the time of catheterization to prevent this complication 5.
Dosing Algorithm
Initial therapy: 2.5 mg subcutaneous daily 1, 2
With fibrinolytic therapy: 2.5 mg IV bolus, then 2.5 mg subcutaneous daily starting the next day 1, 2
Contraindications:
- CrCl <30 mL/min (absolute contraindication) 1, 2
- Body weight <50 kg for prophylaxis 6
- Active major bleeding 6
Net Clinical Benefit
The combined analysis of OASIS-5 and OASIS-6 (26,512 patients) demonstrated fondaparinux superiority across the full ACS spectrum 7:
- Reduced composite death/MI/stroke: 7.2% vs 8.0% (HR 0.91, p=0.03)
- Reduced major bleeding: 2.1% vs 3.4% (HR 0.59, p<0.00001)
- Superior net clinical outcome: 9.3% vs 11.1% (HR 0.83, p<0.0001)
Common Pitfalls to Avoid
- Do not use fondaparinux if primary PCI is planned - switch to UFH, enoxaparin, or bivalirudin instead 1
- Do not dose in severe renal impairment - fondaparinux is renally cleared and contraindicated with CrCl <30 mL/min 1, 6
- Add UFH if emergent PCI becomes necessary - prevents catheter thrombosis without losing fondaparinux's bleeding benefit 5
- Continue for hospital duration (maximum 8 days) or until revascularization when used with fibrinolytics 1, 2
The evidence strongly supports fondaparinux as the preferred anticoagulant when bleeding risk reduction is prioritized and primary PCI is not the intended strategy, offering a mortality benefit through its superior safety profile while maintaining anti-ischemic efficacy.